Information Provided By:
Fly News Breaks for August 1, 2019
Aug 1, 2019 | 05:24 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Vertex Pharmaceuticals to $230 from $217 citing the company's "big" cystic fibrosis sales beat in Q2. . New reimbursement agreements led to Orkambi growth and Vertex raised 2019 cystic fibrosis sales guidance, Tenthoff tells investors in a research note. The analyst is confident in TripleRx approval and reiterates an Overweight rating on Vertex shares.
News For VRTX From the Last 2 Days
There are no results for your query VRTX